Bristol Myers Squibb

News

Bristol Myers Squibb now has positive phase 3 data under its belt for celmod mezigdomide, as it waits for an FDA verdict on lead drug iberdomide.

News

Bristol Myers Squibb could be months away from bringing the first 'celmod' to market, as the FDA starts a review of iberdomide for multiple myeloma.

News

Recent developments in biopharma AI include an alliance between Thermo and Datavant, plus news from Insilico, Evinova, BPGbio, Evogene, and AMPLY.

News

Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.

News

Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after two positive phase 3 trials.

News

Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.